BiotechTube
PentixaPharm

PentixaPharm

Würzburg, Germany· Est.
pentixapharm.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $27.5M

Overview

PentixaPharm is a German radiopharmaceutical company advancing a targeted theranostic platform centered on the CXCR4 receptor. Its pipeline features two Phase-III-ready candidates: PentixaFor, a diagnostic PET imaging agent, and PentixaTher, a therapeutic radiopharmaceutical, with programs spanning hematological cancers, solid tumors, and endocrine disorders like primary aldosteronism. The company has achieved significant clinical validation, with its diagnostic administered to over 2,500 patients, and is progressing toward pivotal Phase III trials following recent FDA regulatory feedback. Backed by a team of 80 employees with deep industry expertise, PentixaPharm is positioning itself as a leader in CXCR4-targeted radiopharmaceuticals.

OncologyCardiovascularEndocrine

Technology Platform

Peptide-based radiopharmaceutical theranostic platform targeting the CXCR4 receptor. Uses identical targeting ligand conjugated to different radioisotopes for diagnostic imaging (e.g., Gallium-68) and targeted radiotherapy (e.g., Lutetium-177).

Funding History

2
Total raised:$27.5M
Series A$25M
Grant$2.5M

Opportunities

The primary aldosteronism diagnostic market offers a near-term commercial opportunity with a superior non-invasive product.
In oncology, the broad overexpression of CXCR4 across more than 20 cancer types creates a large addressable market for both the diagnostic and therapeutic, particularly in hematological malignancies with high unmet need.

Risk Factors

Key risks include clinical failure in upcoming pivotal Phase III trials, regulatory hurdles, and the challenge of changing clinical practice for diagnosing primary aldosteronism.
As a pre-revenue company, it also faces financial risk in securing sufficient capital to fund late-stage development and potential commercialization.

Competitive Landscape

PentixaPharm appears to be a first-mover with a CXCR4-targeted theranostic pair, though competition may emerge from other radiopharmaceutical companies and targeted therapy developers. Its main competitive advantages are the extensive clinical validation of its diagnostic (2,500+ patients) and the integrated theranostic approach, which is becoming a gold standard in nuclear medicine.

More companies in Radiopharmaceuticals →More companies in Germany →